Trandolapril and endothelin antagonist LU-135252 in the treatment of the fructose-induced hypertensive, hyperinsulinemic, hypertriglyceridemic rat

American Journal of Hypertension

Volumn 16, Issue 4, 2003, Pages 324-328

  Ezra Nimni, Orit ^a   Ezra, David ^a   Peleg, Edna ^a   Munter, Klaus ^b   Rosenthal, Talma ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b Knoll AG   (Germany)

Author keywords

Angiotensin converting enzyme inhibitor; Endothelin antagonist; Rats; Renin angiotensin system; Trandolapril

Indexed keywords

ANGIOTENSIN; BOSENTAN; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; FRUCTOSE; INSULIN; RENIN; TRANDOLAPRIL; TRIACYLGLYCEROL;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; CARBOHYDRATE INTAKE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIETARY INTAKE; DISEASE MODEL; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TAIL CUFF METHOD; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0037381594     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(03)00003-7     Document Type: Article

References (40)

1. A) receptor antagonist in conscious rats. J Cardiovasc Pharmacol 1992;20:940-948.
2. Bird EJ, Moreland SD, Waldron TL, Powell JR: Antihypertensive effects of a novel endothelin-A receptor antagonist in rats. Hypertension 1995;25:1191-1195.
3. Douglas SA, Gellai M, Ezekiel M, Feuerstein GZ, Elliott JD, Ohlstein EH: Antihypertensive actions of the novel nonpeptide endothelin receptor antagonist SB 209670. Hypertension 1995;25:818-822.
4. A-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats. Br J Pharmacol 1997;121:935-940.
5. Schiffrin EL: Endothelin: role in experimental hypertension. J Cardiovasc Pharmacol 2000;35(Suppl 2):S33-S35.
6. Richard V, Hogie M, Clozel M, Loffler BM, Thuillez C: In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation 1995;91:771-775.
7. Donckier JE, Stoleru EL, Hayashida W, van Mechelen H, Selvais P, Galanti L, Clozel P, Ketelslegers JM, Pouleur H: Role of endogenous endothelin-1 in experimental renal hypertension in dogs. Circulation 1995;92:96-113.
8. Donckier JE, Massart PE, Hodeige D, van Mechelen H, Clozel JP, Laloux O, Ketelslegers JM, Charlier AA, Heyndrickx GR: Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition. Circulation 1997;96:1250-1256.
9. Massart PE, Hodeige D, van Mechelen H, Charlier AA, Ketelslegers JM, Heyndrickx GR, Donckier JE: Angiotensin II and endothelin-1 receptor antagonists have cumulative hypotensive effects in canine PAGE hypertension. J Hypertens 1998;16:835-841.
10. Munter K, Ehmke H, Kirchengast M: Maintenance of blood pressure in normotensive dogs by endothelin. Am J Physiol 1999;276:H1022-H1027.
11. Ferri C, Pittoni V, Piccoli A, Laurenti O, Cassone MR, Bellini C, Properzi G, Valesini G, De Mattia G, Santucci A: Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J Clin Endocrinol Metab 1995;80:829-835.
12. Piatti PM, Monti LD, Conti M, Baruffaldi L, Galli L, Phan CV, Guazzini B, Pontiroli AE, Pozza G: Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes 1996;45:316-321.
13. Hopfner RL, Misurski D, Wilson TW, McNeill JR, Gopalakrishnan V: Insulin and vanadate restore decreased plasma endothelin concentrations and exaggerated vascular responses to normal in the streptozotocin diabetic rat. Diabetologia 1998;41:1233-1240.
14. Verma S, Bhanot S, Mcneill JH: Effect of chronic endothelin blockade in hyperinsulinemic hypertensive rats. Am J Physiol 1995;269:H2017-H2021.
15. Wu SQ, Hopfner RL, McNeill JR, Wilson TW, Gopalakrishnan V: Altered paracrine effect of endothelin in blood vessels of the hyperinsulinemic, insulin resistant obese Zucker rat. Cardiovasc Res 2000;45:994-1000.
16. Hu RM, Levin ER, Pedram A, Harrison JL, Frank HJ: Insulin stimulates production and secretion of endothelin from bovine endothelial cells. Diabetes 1993;42:351-358.
17. Anfossi G, Cavalot F, Massucco P, Mattiello L, Mularoni E, Hahn A, Trovati M: Insulin influences immunoreactive endothelin release by human vascular smooth muscle cells. Metabolism 1993;42:1081-1083.
18. Frank HJ, Levin ER, Hu RM, Pedgram A: Insulin stimulates endothelin binding and action on cultured vascular smooth muscle cells. Endocrinology 1993;133:1092-1097.
19. Veniant M, Clozel JP, Hess P, Clozel M: Endothelin plays a role in the maintenance of blood pressure in normotensive guinea pigs. Life Sci 1994;55:445-454.
20. Iglarz M, Matrougui K, Levy BI, Henrion D: Chronic blockade of endothelin ETA receptors improves flow dependent dilation in resistance arteries of hypertensive rats. Cardiovasc Res 1998;39:657-664.
21. Dohi Y, Hahn AWA, Boulanger CM, Buhler FR, Lusher TF: Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension 1992;19:131-137.
22. Chen L, McNiell JR, Wilson TW, Gopalakrishnan V: Heterogeneity in vascular smooth responsiveness to angiotensin II: role of endothelin. Hypertension 1995;26:83-88.
23. Li JS, Schiffrin EL: Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension 1995;25:495-500.
24. Moreau P: Role of endothelin in arterial hypertension from agonists to antagonists. Presse-Med 1997;26:700-702.
25. Li JS, Knafo L, Turgeon A, Garcia R, Schiffrin EL: Effect of endothelin antagonism on blood pressure and vascular structure in renovascular hypertensive rats. Am J Physiol 1996;40:H88-H93.
26. Potter GS, Melaragno MG, Johnson RJ, Fink GD: Evidence for a role of endothelin in the hypertension of experimental chronic renal failure (Abstract). Hypertension 1996;28:542.
27. Moreau P, d'Oscio LV, Shaw S, Hiroyuki T, Barton M, Luscher TF: Angiotensin II increases tissue endothelin and induces vascular hypertrophy. Reversal by ETA-receptor antagonist. Circulation 1997;96:1593-1597.
28. A receptor blockade in angiotensin II induced hypertension. Hypertension 1997;29:435-441.
29. Balakrishnan SM, Wang HD, Gopalakrishnan V, Wilson TW, McNeill RJ: Effect of an endothelin antagonist on hemodynamic responses to angiotensin II. Hypertension 1996;28:806-809.
30. Barton M, Shaw SG, d'Uscio LV, Moreau P, Luscher TF: Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 1997;238:861-865.
31. Chua BHL, Chua CC, Diglio CA, Siu BB: Regulation of endothelin-1 mRNA by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1993;1178:201-206.
32. Juan CC, Fang VS, Hsu YP, Huang YJ, Hsia DB, Yu PC, Kwok CF, Ho LT: Overexpression of vascular endothelin-1 and endothelin A receptors in a fructose induced hypertensive rat model. J Hypertens 1998;16:1775-1782.
33. Erlich Y, Rosenthal T: Effect of angiotensin-converting enzyme inhibitors on fructose induced hypertension and hyperinsulinemia in rats. Clin Exp Pharmacol Physiol 1995;27(Suppl l):S347-S349.
34. Erlich Y, Rosenthal T: Contribution of nitric oxide to the beneficial effects of converting enzyme inhibitors. Hypertension 1990;28:754-757.
35. Tobey TA, Mondon CE, Zavaroni I, Reaven GM: Mechanism of insulin resistance in fructose fed rats. Metabolism 1982;31:608-612.
36. Leighton B, Sanderson AL, Young ME, Radda GK, Boehm EA, Clark JF: Effects of treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor trandolapril and the calcium antagonist verapamil on the sensitivity of glucose metabolism to insulin in rat soleus muscle in vitro. Diabetes 1996;45(Suppl 1):S120-S124.
37. Benigni A, Corna D, Maffi R, Benedetti G, Zoja C, Remuzzi G: Renoprotective effect of contemporary blocking of angiotensin II antagonist and endothelin-1 in rats with membranous nephropathy. Kidney Intern 1998;54:353-359.
38. A receptor antagonist LU-135252 and the angiotensin converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model. J Pharmacol Exp Ther 2000;293:351-359.
39. Braszko JJ, Paslawski L, Karwowska-Polecka W, Holownia A: Trandolapril attenuates acquisition of conditioned avoidance in rats. Pol J Pharmacol 2000;52:195-201.
40. Sassy-Prigent C, Heudes D, Jouquey S, Auberval D, Belair MF, Michel O, Hamon G, Bariety J, Bruneval P: Morphometric detection of incipient glomerular lesions in diabetic nephropathy in rats. Protective effect of ACE inhibition. Lab Invest 1995;73:64-71.